Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

Background: Primary analyses of the phase III BrighTNess trial showed addition of carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved pathological complete response (pCR) rates with manageable acute toxicity in patients with triple-negative breast cancer (TNBC). Her...

Full description

Bibliographic Details
Main Authors: Dunbar, M. (Author), Geyer, C.E (Author), Golshan, M. (Author), Harkness, C. (Author), Huober, J. (Author), Loibl, S. (Author), Lorenzo, J.P (Author), Maag, D. (Author), McIntyre, K. (Author), Metzger, O. (Author), O'Shaughnessy, J. (Author), Rastogi, P. (Author), Rugo, H.S (Author), Sikov, W.M (Author), Sohn, J.H (Author), Symmans, W.F (Author), Untch, M. (Author), Wolmark, N. (Author), Wright, G.S (Author), Yardley, D. (Author), Young, R. (Author)
Format: Article
Language:English
Published: Elsevier Ltd 2022
Subjects:
carboplatin
neoadjuvant chemotherapy
phase III
triple-negative breast cancer
veliparib
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items